Literature DB >> 19635961

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.

Helio S Sader1, Paul D Fey, Ajit P Limaye, Nancy Madinger, Douglas N Fish, George Pankey, James Rahal, Michael J Rybak, David R Snydman, Lisa L Steed, Ken Waites, Ronald N Jones.   

Abstract

Vancomycin MIC creep has been reported by some institutions but not confirmed in large surveillance studies. We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference MIC methods. Nine hospitals (one in each U.S. census region) randomly selected bloodstream MRSA strains (target, 40/year) from 2002 to 2006. MICs were determined by the reference broth microdilution method using incremental dilutions (eight for each log(2) dilution step). Isolates for which vancomycin MICs were >1 microg/ml were typed by pulsed-field gel electrophoresis (PFGE). The vancomycin MIC mode was either 0.625 microg/ml (for eight hospitals) or 0.813 microg/ml (for one hospital), and vancomycin MIC results for 72.9% of strains were between 0.563 and 0.688 microg/ml. No yearly variation in the central tendency of vancomycin MICs for the wild-type population in any medical center was observed; however, when data were analyzed by the geometric mean statistic, vancomycin MIC increases (at three sites) and declines (at three sites) were observed. The daptomycin MIC mode varied from 0.156 microg/ml (2003 to 2005) to 0.219 microg/ml (2002 and 2006), and MIC results for 83.5% (80.3 to 89.2% in each of the centers) of isolates fell between these values. Among PFGE-typed strains, 43 of 55 (78%; from seven hospitals) showed a pattern consistent with that of the USA100 clone, which was represented by all strains from two hospitals and 64 to 88% of strains from five other medical centers; only one strain (2%) was USA300. In conclusion, the perception of MIC creep may vary according to the methods used to analyze the data. Geometric mean MIC data revealed a possible, very-low-level MIC creep at three of nine sites over the 5-year period, which was not evident using modal MICs or the data from all nine hospitals (+0.02 mug/ml). The occurrence of isolates for which the vancomycin MIC was >1 microg/ml was very unusual, with no increased trend, but these organisms were usually clonal (USA100).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635961      PMCID: PMC2764224          DOI: 10.1128/AAC.00616-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States.

Authors:  Fred C Tenover; Linda K McDougal; Richard V Goering; George Killgore; Steven J Projan; Jean B Patel; Paul M Dunman
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002.

Authors:  Jérôme Robert; Roland Bismuth; Vincent Jarlier
Journal:  J Antimicrob Chemother       Date:  2006-01-12       Impact factor: 5.790

Review 3.  Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.

Authors:  Ronald N Jones
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

4.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

5.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

Review 6.  Limitations of vancomycin in the management of resistant staphylococcal infections.

Authors:  Marin H Kollef
Journal:  Clin Infect Dis       Date:  2007-09-15       Impact factor: 9.079

Review 7.  Epidemiology of methicillin-resistant staphylococci in Europe.

Authors:  S Stefani; P E Varaldo
Journal:  Clin Microbiol Infect       Date:  2003-12       Impact factor: 8.067

8.  How clonal is Staphylococcus aureus?

Authors:  Edward J Feil; Jessica E Cooper; Hajo Grundmann; D Ashley Robinson; Mark C Enright; Tony Berendt; Sharon J Peacock; John Maynard Smith; Michael Murphy; Brian G Spratt; Catrin E Moore; Nicholas P J Day
Journal:  J Bacteriol       Date:  2003-06       Impact factor: 3.490

9.  Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database.

Authors:  Linda K McDougal; Christine D Steward; George E Killgore; Jasmine M Chaitram; Sigrid K McAllister; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

View more
  46 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection.

Authors:  Clare E Miller; Rahul Batra; Ben S Cooper; Amita K Patel; John Klein; Jonathan A Otter; Theodore Kypraios; Gary L French; Olga Tosas; Jonathan D Edgeworth
Journal:  Clin Infect Dis       Date:  2011-12-20       Impact factor: 9.079

3.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

4.  Hydrophobic interactions modulate antimicrobial peptoid selectivity towards anionic lipid membranes.

Authors:  Konstantin Andreev; Michael W Martynowycz; Mia L Huang; Ivan Kuzmenko; Wei Bu; Kent Kirshenbaum; David Gidalevitz
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-04-03       Impact factor: 3.747

Review 5.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

6.  Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus.

Authors:  Mark C Kruzel; Cole T Lewis; Kerry J Welsh; Evan M Lewis; Nicola E Dundas; John F Mohr; Lisa Y Armitige; Audrey Wanger
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

7.  PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.

Authors:  Krishna Muppidi; Jeffrey Wang; Guru Betageri; Andrew S Pumerantz
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

Review 8.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.

Authors:  P Tattevin; A Saleh-Mghir; B Davido; I Ghout; L Massias; C Garcia de la Maria; J M Miró; C Perronne; F Laurent; A C Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.